MarketPulse
O

$ORKA

2 articles found
1 positive
0 negative
1 neutral
BenzingaBenzinga··Not Specified

Oruka Therapeutics Plans $500M Capital Raise via Public Offering

Oruka Therapeutics plans $500M public offering plus $75M underwriter option to fund monoclonal antibody pipeline for psoriasis and inflammatory conditions.
ORKAmonoclonal antibodypublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

90+ Companies Racing to Transform Psoriasis Treatment Landscape

Over 90 pharmaceutical companies are advancing 100+ psoriasis drugs through clinical trials, with major players like Takeda and Alumis posting positive Phase III results.
SNGXTAKFBLGCANFALMS+1clinical trialsbiologics